Somatuline Predictive Factors in Acromegaly and NET
Somatuline Predictive Factors in Acromegaly and NET
The aim of the study is to identify predictive factors for the response to Lanreotide
 treatment in Acromegaly as well as in Neuroendocrine Tumours.
Inclusion Criteria:

 -  Written informed consent (also mandatory in case of retrospective documentation of
 subject data)

 -  Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on
 treatment with ATG

 Exclusion Criteria:

 -  The subject has already been included in this study

 -  Participation in an interventional trial